Bortezomib in relapsed or refractory Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 74-76

  Chen, Christine ^a   Kouroukis, C Tom ^b   White, Darrell ^c   Voralia, Michael ^d   Stadtmauer, Edward ^e   Stewart, A Keith ^f   Wright, John ^g   Powers, Jean ^h   Walsh, Wendy ^h   Eisenhauer, Elizabeth ^h  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d Saskatoon Cancer Center   (Canada)

^e Eastern Cooperative Oncology Group   (United States)

^f MAYO CLINIC   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h Queen's Cancer Research Institute   (Canada)

Author keywords

Hyperviscosity; Neuropathy; Neutropenia; Second line treatment; Thrombocytopenia; Waldenstr m

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN M; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; BLEEDING; BLOOD VISCOSITY; CLINICAL TRIAL; DRUG EFFECT; HUMAN; INFECTION; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; REVIEW;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; PYRAZINES; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649541021     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.019     Document Type: Article

References (11)

1. Hatjiharissi E, Hgo H, Leontovich A, et al. Proteomic analysis of Waldenstrom Macroglobulinemia. Cancer Res 2007; 67:3777-84.
2. Mitsiades C, Mitsiades N, Richardson P, et al. Novel biologically based therapies in Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:309-12.
3. Dimopoulos M, Anagnostopoulos A, Kyrtsonis M, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90:1655-8.
4. Chen C, Kouroukis C, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's Macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1570-5.
5. Cheson B, Horning S, Coiffier B, et al. Report of the International Workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:1244-53.
6. Treon S, Hunter Z, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. Clin Cancer Res 2007; 13:3320-5.
7. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
8. O'Connor O, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-84.
9. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-75.
10. Mitsiades N, Mitsiades C, Poulaki V, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-80.
11. Mitsiades N, Mitsiades C, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci 2002; 99:14374-9.